B-cell lymphoma immunoglobulin idiotype (Id)

The B-cell lymphoma immunoglobulin idiotype (Id) refers to the unique set of antigenic determinants located within the variable regions (V-regions) of the immunoglobulin molecule expressed on the surface of malignant B cells (Levy et al., 1982, PMID: 7041216). Because each B-cell lymphoma arises from a single transformed B-cell clone, the idiotype serves as a truly tumor-specific neoantigen that is absent from normal B cells and other tissues (Bendandi et al., 1999, PMID: 10481244). Biologically, the idiotype is a component of the B-cell receptor (BCR) complex, which is essential for mediating survival and proliferation signals in various B-cell malignancies (Kwak et al., 1992, PMID: 1383820). In therapeutic development, the idiotype has been targeted primarily through personalized active immunotherapy, where patient-specific Id protein is harvested and used as a vaccine to stimulate the host's immune system to recognize and destroy the malignant clone (Schuster et al., 2011, PMID: 21900502). Despite the high specificity of this target, clinical success has been hampered by the logistical challenges of custom manufacturing and the emergence of tumor escape variants that downregulate or mutate the targeted idiotype (Inoges et al., 2006, PMID: 16757680).

Other names

Tumor-specific idiotypeB-cell receptor idiotypeBCR idiotypeIdiotypic determinantSurface immunoglobulin idiotype

Active immunotherapy involving the administration of patient-specific idiotype protein, typically conjugated to a carrier protein like Keyhole Limpet Hemocyanin (KLH) and administered with an adjuvant (e.g., GM-CSF), to induce a personalized T-cell and B-cell mediated anti-tumor immune response (Schuster et al., 2011, PMID: 21900502).